Novartis AG (NYSE:NVS – Free Report) – Stock analysts at Zacks Research raised their Q4 2026 earnings estimates for shares of Novartis in a note issued to investors on Monday, August 24th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $2.21 for the quarter, up from their previous forecast of $2.20. The consensus estimate for Novartis’ current full-year earnings is $8.85 per share. Zacks Research also issued estimates for Novartis’ Q3 2027 earnings at $2.45 EPS, FY2027 earnings at $9.68 EPS and Q1 2028 earnings at $2.55 EPS.
Novartis (NYSE:NVS – Get Free Report) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. The firm had revenue of $14.95 billion during the quarter.
Novartis Stock Performance
Shares of NVS stock opened at $160.09 on Wednesday. The stock’s 50-day moving average is $154.66 and its two-hundred day moving average is $153.77. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.67 and a current ratio of 0.86. Novartis has a 1 year low of $121.57 and a 1 year high of $170.46. The firm has a market cap of $305.47 billion, a price-to-earnings ratio of 24.15, a PEG ratio of 2.71 and a beta of 0.45.
Hedge Funds Weigh In On Novartis
Several institutional investors have recently added to or reduced their stakes in the stock. J.W. Cole Advisors Inc. increased its holdings in shares of Novartis by 0.6% in the 4th quarter. J.W. Cole Advisors Inc. now owns 10,577 shares of the company’s stock worth $1,348,000 after purchasing an additional 64 shares in the last quarter. Roundview Capital LLC lifted its holdings in shares of Novartis by 2.5% during the fourth quarter. Roundview Capital LLC now owns 2,711 shares of the company’s stock valued at $374,000 after purchasing an additional 66 shares in the last quarter. CPC Advisors LLC lifted its holdings in shares of Novartis by 4.6% during the second quarter. CPC Advisors LLC now owns 1,516 shares of the company’s stock valued at $238,000 after purchasing an additional 66 shares in the last quarter. IMA Advisory Services Inc. boosted its position in shares of Novartis by 10.9% during the fourth quarter. IMA Advisory Services Inc. now owns 710 shares of the company’s stock valued at $98,000 after buying an additional 70 shares during the last quarter. Finally, Moody National Bank Trust Division boosted its position in shares of Novartis by 4.2% during the second quarter. Moody National Bank Trust Division now owns 1,802 shares of the company’s stock valued at $282,000 after buying an additional 72 shares during the last quarter. Institutional investors and hedge funds own 13.12% of the company’s stock.
About Novartis
Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.
The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.
Recommended Stories
- Five stocks we like better than Novartis
- Marzetti Stock Confirms Reversal on Earnings Strength, Dividend Growth
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.
